Oral valdecoxib and injected parecoxib for acute postoperative pain: A quantitative systematic review

被引:61
作者
Jodie Barden
Jayne E Edwards
Henry J McQuay
R Andrew Moore
机构
[1] Pain Res./Nuffield Dept. of Anaesth., University of Oxford, Oxford Radcliffe Hospital, Oxford OX3 7LJ, The Churchill, Headington
关键词
Pain Relief; Rofecoxib; Oxycodone; Ketorolac; Valdecoxib;
D O I
10.1186/1471-2253-3-1
中图分类号
学科分类号
摘要
Background: Clinical trials suggest that cyclo-oxygenase-2 specific inhibitors (coxibs) are an effective treatment for acute postoperative pain. The aims of this systematic review were to examine the evidence for oral valdecoxib and injected parecoxib, and quantify efficacy and adverse effects. Methods: Information from randomized, double-blind studies in acute postoperative pain was sought. The area under the pain relief versus time curve over four to six hours was dichotomized using validated equations to derive the proportion of patients with treatment and placebo with at least 50% pain relief over four to six hours and calculate the number-needed-to-treat (NNT). Information on duration of analgesia and adverse events was also collected. Results: The NNT for one patient to experience at least 50% relief over six hours following a single oral dose of valdecoxib 20 mg and 40 mg was 1.7 (1.4 to 2.0) and 1.6 (1.4 to 1.8) respectively. The NNT for one patient to have at least 50% relief over four to six hours with parecoxib 20 mg IV and 40 mg IV was 3.0 (2.3 to 4.1) and 2.3 (2.0 to 2.6) respectively. Mean time to remedication (weighted by trial size) was > 24 hours with valdecoxib 40 mg, 8.7 hours with parecoxib 40 mg IV and 1.7 to 1.8 hours with placebo. There were no statistical differences between treatment and placebo for any adverse effect. Conclusion: Both oral valdecoxib and injected parecoxib are effective treatments for acute postoperative pain. © 2003 Barden et al; licensee BioMed Central Ltd.
引用
收藏
页数:9
相关论文
共 39 条
[1]  
Meade E.A., Smith W.L., deWitt D.L., Et al., Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzymes by aspirin and other non-steroidal anti-inflammatory drugs, J. Biol. Chem., 268, pp. 6610-6614, (1993)
[2]  
Chan C.C., Boyce S., Bridea C., Et al., Rofecoxib: A potent and orally active cyclooxygenase-2 inhibitor - Pharmalogical and biolchemical profiles, J. Pharmacol. Exp. Ther., 290, pp. 551-560, (1999)
[3]  
Hawkey C.J., COX-2 inhibitors, Lancet, 353, pp. 307-314, (1999)
[4]  
Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Et al., Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis, N. Engl. J. Med., 343, pp. 1520-1528, (2000)
[5]  
Barden J., Edwards J.E., McQuay H.J., Moore R.A., Single-dose rofecoxib for acute postoperative pain in adults: A quantitative systematic review, BMC Anesthesiol., 2, 1, (2002)
[6]  
Ormrod D., Wellington K., Wagstaff A.J., Valdecoxib, Drugs, 62, pp. 2059-2071, (2002)
[7]  
Cheer S.M., Goa K.L., Parecoxib (parecoxib sodium), Drugs, 61, pp. 1133-1141, (2001)
[8]  
Talley J.J., Brown D.L., Carter J.S., 4-[5-Methyl-3-phenyl-lisoxazol-4-yl]-benzenesulfonamide, valdecoxib: A potent and selective inhibitor of COX-2, J. Med. Chem., 9, pp. 775-777, (2000)
[9]  
Tramer M.R., Williams J.E., Carroll D., Wiffen P.J., Moore R.A., McQuay H.J., Comparing analgesic efficacy of non-steroidal anti-inflammatory drugs given by different routes in acute and chronic pain: A qualitative systematic review, Acta Anaesthesiol. Scandinavica, 42, pp. 71-79, (1998)
[10]  
Moore R.A., Gavaghan D., Tramer M.R., Collins S.L., McQuay H.J., Size is everything - Large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects, Pain, 78, pp. 209-216, (1998)